(Q41673534)

6 October 2017

1 reference

title

New horizons in the treatment of tuberculosis (English)

1 reference

6 October 2017

1 reference

C E Barry

1

1 reference

6 October 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

6 October 2017

published in

Biochemical Pharmacology

1 reference

6 October 2017

volume

54

1 reference

6 October 2017

issue

11

1 reference

6 October 2017

page(s)

1165-1172

1 reference

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

7 January 2021

The new tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Tuberculosis: commentary on a reemergent killer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Origin and Interstate Spread of a New York City Multidrug-Resistant Mycobacterium tuberculosis Clone Family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Dormancy of Mycobacterium tuberculosis and latency of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Prospects for new interventions in the treatment and prevention of mycobacterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Transformation with katG restores isoniazid-sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Positive control of a regulon for defenses against oxidative stress and some heat-shock proteins in Salmonella typhimurium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Mycobacterium tuberculosis is a natural mutant with an inactivated oxidative-stress regulatory gene: implications for sensitivity to isoniazid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

An ideR mutant of Mycobacterium smegmatis has derepressed siderophore production and an altered oxidative-stress response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Oxidative stress response and its role in sensitivity to isoniazid in mycobacteria: characterization and inducibility of ahpC by peroxides in Mycobacterium smegmatis and lack of expression in M. aurum and M. tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

The extreme sensitivity of Mycobacterium tuberculosis to the front-line antituberculosis drug isoniazid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Drug sensitivity and environmental adaptation of mycobacterial cell wall components.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Isoniazid Inhibition of the Synthesis of Monounsaturated Long-Chain Fatty Acids in Mycobacterium tuberculosis H37Ra

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

The structure and function of the isoniazid target in M. tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Rifamycin resistance in mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Mycobacterium smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of rifampicin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Molecular basis of rifampin resistance in Mycobacterium leprae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Current problems with tuberculosis treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

The action of antituberculosis drugs in short-course chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Antimycobacterial activity of a series of pyrazinoic acid esters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Synthesis of the Arabinose Donor .beta.-D-Arabinofuranosyl-1-monophosphoryldecaprenol, Development of a Basic Arabinosyl-Transferase Assay, and Identification of Ethambutol as an Arabinosyl Transferase Inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Truncated structural variants of lipoarabinomannan in ethambutol drug-resistant strains of Mycobacterium smegmatis. Inhibition of arabinan biosynthesis by ethambutol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Biogenesis of the mycobacterial cell wall and the site of action of ethambutol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Glycosyltransferases as targets for inhibition of cell wall synthesis in M. tuberculosis and M. avium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

The Envelope of Mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Mycolic acid structure determines the fluidity of the mycobacterial cell wall

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

The biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Identification and functional analysis of CMAS-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Evaluation of the routes of glucose utilization in virulent and avirulent strains of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Nitroimidazole drugs-action and resistance mechanisms I. Mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

The mechanism of nitroimidazole damage to DNA: coulometric evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Electron spin resonance-spin trapping. Detection of superoxide formation during aerobic microsomal reduction of nitro-compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

MycDB: an integrated mycobacterial database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900163-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-2952(97)00163-9

1 reference

6 October 2017

1 reference